CEACAM5 and colorectal carcinoma: A case report revealed a synergic interaction of SGLT2i and cetuximab in reducing metastatic CRC size and Carcinoembryonic Antigen (CEA) levels [186], whilst tofogliflozin suppressed CRC development and β-catenin accrual in diabetic mice [187].